Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences Corp (EW) officer trades company stock through option exercise and sale. On 12/10/2025, the reporting person, a corporate vice president for strategy and corporate development, exercised an employee stock option for 11,340 shares of common stock at an exercise price of $59.2567 per share, then sold the same 11,340 shares at a weighted average price of $83.8255 per share in open-market transactions. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025. After the transactions, the insider directly held 50,356.3707 shares, plus 38,817.6991 shares through a 401(k), 135,152 shares held by a trust, and 45,360 employee stock options.
Edwards Lifesciences CEO and director reported several equity transactions in company stock. On December 8, 2025, the insider exercised an employee stock option for 25,350 shares of common stock at an exercise price of $59.2567 per share, then sold 21,487 shares at a weighted average price of $85.2146. The option had been granted in 2019 under the company’s long-term stock incentive program.
On December 9, 2025, the insider transferred 3,863 shares from direct ownership and the same amount was recorded as held indirectly in a trust. On December 10, 2025, the trust sold 3,863 shares at $83.45 per share. After these transactions, the filing shows remaining direct and indirect holdings, including shares held through a trust and a 401(k). All reported trades were made under a Rule 10b5-1 trading plan adopted on February 28, 2025.
Edwards Lifesciences insider plans Rule 144 stock sale. A holder of Edwards Lifesciences common stock filed a notice to sell 11,340 shares through broker Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $950,582. The filing shows 580,300,000 common shares outstanding for the issuer. The shares to be sold were acquired on 12/10/2025 through an employee stock option exercise, using a broker-facilitated cashless exercise structure.
Edwards Lifesciences has a shareholder filing a Form 144 notice to sell up to 3,863 common shares through Charles Schwab on or about December 10, 2025, with an aggregate market value of $322,367. The shares to be sold were acquired on December 8, 2025 via a restricted stock lapse as equity compensation from Edwards Lifesciences Corporation.
During the prior three months, the same seller disposed of 21,487 Edwards Lifesciences shares on December 8, 2025 for gross proceeds of $1,831,006. Edwards Lifesciences had 580,300,000 shares outstanding, providing context for the relative size of these planned and recent sales.
Edwards Lifesciences reported an insider stock transaction by its Chief Financial Officer, who serves as Corporate Vice President. On December 9, 2025, the executive exercised 7,700 employee stock options at an exercise price of $59.2567 per share, acquiring the same number of common shares. On the same date, the executive sold 7,700 shares of common stock at a weighted average price of $84.4691 per share. These trades were carried out under a Rule 10b5-1 trading plan adopted on July 29, 2025. After the reported transactions, the executive directly owned 39,898 shares of common stock and held 266,318 shares indirectly through a trust, along with 39,000 employee stock options that remained beneficially owned.
Edwards Lifesciences Corp executive reports small stock sale
An officer of Edwards Lifesciences Corp, serving as CVP, JAPAC, reported a routine sale of company stock. On 12/08/2025, the reporting person sold 583 shares of Edwards Lifesciences common stock at a price of $86.01 per share. After this transaction, the insider reported beneficial ownership of 17,562.8708 shares of common stock, held directly. The filing notes that it reflects changes in beneficial ownership only and does not identify any other securities of Edwards Lifesciences that may be beneficially owned by this person.
Edwards Lifesciences Corporation insider filed a Form 144 notice for a planned sale of common stock. The filing covers up to 583 shares of common stock to be sold through Charles Schwab & Co., Inc. on or about 12/08/2025 on the NYSE, with an aggregate market value of $50,144.00. The issuer has 580,300,000 shares of common stock outstanding.
The shares to be sold were acquired through equity compensation, specifically restricted stock lapses of 316 shares on 09/14/2024 and 267 shares on 09/14/2025 from Edwards Lifesciences Corporation. The seller represents that they are not aware of any material adverse, nonpublic information about the company’s operations.
Edwards Lifesciences Corporation (EW) has a shareholder filing a notice to sell 21,487 shares of its common stock under Rule 144. The shares are to be sold through broker Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $1,831,006 and 580,300,000 common shares stated as outstanding. The seller acquired these shares on 12/08/2025 through an employee stock option exercise, using a broker payment for a cashless exercise on the same date. The person signing the notice represents that they are not aware of any undisclosed material adverse information about Edwards Lifesciences’ current or prospective operations.
Edwards Lifesciences (EW) reported an insider equity grant. The company’s SVP, Corporate Controller, acquired 1,160 shares of common stock at $0.0000 on 11/13/2025.
The filing explains these restricted stock units were granted under the Long‑Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Following the transaction, the officer’s beneficial ownership was 9,183.074 shares, held directly. The filing also notes quarterly acquisitions under the Employee Stock Purchase Plan.
Edwards Lifesciences (EW): Form 144 filed for a proposed sale. Larry L. Wood filed a notice to sell 26,850 shares of Edwards Lifesciences common stock, with an aggregate market value of $2,285,355.00. The approximate sale date is 11/11/2025, via Charles Schwab & Co., Inc. on the NYSE.
The shares to be sold were acquired on 11/11/2025 through an employee stock option exercise with a broker payment for cashless exercise. In the past three months, the filer sold 8,950 shares on 08/18/2025 for $698,679.00 and 8,950 shares on 10/16/2025 for $653,522.00. Shares outstanding were 580,300,000; this is a baseline figure, not the amount being sold.